NCT02686944已完成1 期
A Phase I Open-label Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax in Patients With Progressing Gastrointestinal Stromal Tumors (GIST) During Ongoing Second, Third or Fourth Line Treatment With Tyrosine Kinase Inhibition Therapy. A Prospective Single Armed, Open Label Phase I Safety and Efficacy Study
Mendus2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2016年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- Changes in vital signs (heart rate, blood pressure, body temperature)
研究概览
简要总结
The study is a prospective single armed, open label phase I study. Patients with advanced or metastatic GIST and tumor progression despite ongoing treatment with second, third or fourth line TKI treatment, and with at least one measureable tumor lesion, will be eligible for the study. A maximum of 12 patients will be included in this study. The patients will continue with TKI treatment until the 3 months follow up visit. If further tumor progression TKI will be withdrawn but if stable disease or objective response the patient will continue with TKI until progress. The investigational product Intuvax will be injected into a tumor lesion at two or three treatment occasions; day 1, 14 days (±3 days) after the first vaccination, and 28 days (±3 days) after the second vaccination (patient 7-12 only). Intuvax will be injected in a viable part of the tumor, using ultrasound-guided or CT technique for correct administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open Label
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be informed of the nature of the study and have provided written informed consent.
- •At least 18 years of age.
- •Diagnosis of GIST (according to modified NIH criteria, 2011) where curative excision is no longer an option, i.e. confirmed unresectable or metastatic GIST, and that has progressed on second, third or fourth line tyrosine kinase inhibitor (TKI) treatment.
- •Radiologically measurable tumor(s), i.e at least 3 cm in longest uni-dimensional diameter as measured by CT
- •Clinical and/or CT verified disease progression despite ongoing second, third or fourth line treatment with a TKI
- •Female who has been post-menopausal for more than one (1) year or female of childbearing potential using a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills]) during study participation. Female of childbearing potential must have a negative blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax, or Male agreeing to use condoms during the study participation or male having a female partner who is using a highly efficient method of contraception as described above during the partner's study participation.
排除标准
- •Performance status > ECOG 2
- •Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxia or other serious reaction)
- •Known major reaction/adverse event in connection with previous transfusions of blood products
- •Active autoimmune disease requiring treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.
- •Tested positive for HIV
- •Active virus disease (HBV and HCV).
- •Ongoing infection that requires treatment with parenteral antibiotics or antiviral medication
- •Corticosteroid treatment per os exceeding 10mg/day within 7 days prior to the first injection of Intuvax. Inhaled, intranasal and local steroids accepted.
- •Inadequate laboratory parameters, i.e.:
- •B-Leukocyte count < 3.0 x109/L
- •B-Platelet count < 75 x109/L
- •B-Hemoglobin < 100 g/L
- •P-Prothrombincomplex (PK) >1.4
- •P-APT time outside normal limit
- •Previous organ transplantation
- •Pregnant or lactating women
- •Life expectancy less than 3 months.
- •Investigational treatment (within 28 days) prior to the first injection of Intuvax
- •Known blood dyscrasia (bleeding complication)
- •Prior history of invasive cancer within 5 years before screening, except for adequately treated in situ carcinomas or non melanoma skin cancer
- •History of alcohol or substance abuse
- •patient will not be available for follow up assessments
- •Any other reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.
结局指标
主要结局
Changes in vital signs (heart rate, blood pressure, body temperature)
时间窗: Up to 12 months after vaccination 1
Changes in lab parameters (hematology and biochemistry) during the study versus baseline
时间窗: Up to 12 months after vaccination 1
Adverse events according to CTCAE v 4.03
时间窗: Up to 12 months after vaccination 1
次要结局
- Progression free survival according to RECIST 1.1(Up to 12 months after vaccination 1)
- Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to mRECIST(Every 3 months up to 12 months after vaccination 1)
- Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to RECIST 1.1.(Every 3 months up to 12 months after vaccination 1)
- Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to Choi criteria(Every 3 months up to 12 months after vaccination 1)
- Progression free survival according to mRECIST(Up to 12 months after vaccination 1)
- Progression free survival according to Choi criteria(Up to 12 months after vaccination 1)
- Changes in WHO-ECOG score(Up to 12 months after vaccination 1)
- Levels of alloimmunization parameters(Up to 3 months after vaccination 1)
- Levels of autoimmunization parameters(Up to 3 months after vaccination 1)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal FunctionUnspecified Adult Solid Tumor, Protocol SpecificNCT01418677Eisai Inc.19
终止
1 期
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid TumorsSolid Tumors, AdultNCT04467853Shanghai East Hospital34
已完成
1 期
A Phase 1 Clinical Study of CU-20401 in Chinese Healthy PopulationHealthy SubjectsNCT05173883Cutia Therapeutics（Wuxi）Co.,Ltd48
已完成
1 期
Special Combination of OBP-301 and PembrolizumabAdvanced Solid TumorNCT03172819Toshihiko Doi22
已完成
1 期
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerAdvanced Lung CancerNCT04672356Innovent Biologics (Suzhou) Co. Ltd.19